Related Experiment Video
Updated: Jun 12, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
The risk for significant creatine kinase elevation with statins
Ryan S Stolcpart1, Kari L Olson, Thomas Delate
1EPIC Systems Corporation, Madison, Wisconsin, USA.
Insights
Simvastatin use, especially at high doses, increases the risk of creatine kinase (CK) elevation compared to lovastatin. This finding is crucial for managing statin therapy and preventing rhabdomyolysis in clinical practice.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Statins (HMG-CoA reductase inhibitors) are vital for cardiovascular disease prevention.
- Rhabdomyolysis, a severe adverse effect of statins, involves significant creatine kinase (CK) elevation.
- Real-world data on statin-associated rhabdomyolysis risk is limited.
Purpose of the Study:
- To investigate the risk of CK elevation in patients using statins within a clinical practice setting.
- To identify and evaluate potential risk factors associated with statin-induced CK elevation.
Main Methods:
- A case-control study involving patients prescribed lovastatin or simvastatin.
- Cases (n=183) had CK > or =10x ULN; controls (n=1830) did not, matched by statin purchase date.
- Multivariate conditional logistic regression analyzed associations between statins, dose, demographics, comorbidities, and medications.
Main Results:
- Simvastatin use showed a higher likelihood of CK elevation (> or =10x ULN) than lovastatin (aOR 4.6).
- High-dose simvastatin (80 mg) increased risk (aOR 2.7) compared to simvastatin 40 mg, particularly with interacting medications.
- Lovastatin 80 mg also showed increased risk when used with interacting medications.
Conclusions:
- Simvastatin is associated with a greater risk of significant CK elevation than lovastatin.
- High-dose simvastatin poses a higher risk for CK elevation compared to lower doses of either statin.
- These findings highlight the importance of dose and drug interactions in statin-associated myopathy.
Background:
The HMG-CoA reductase inhibitors (statins) are effective for reducing long-term cardiovascular morbidity and mortality in both primary and secondary prevention. The most serious adverse reaction is significant elevation of creatine kinase (CK) leading to rhabdomyolysis. The incidence of CK elevation is low in randomized, controlled trials. The rate may be higher in 'real-world', less controlled settings. Data on the risks of statin-associated rhabdomyolysis in 'real-world' practice settings are limited.
Objective:
The aim of this study was to examine the risk for CK elevation among statin users in a clinical practice setting. Potential risk factors were identified and evaluated to quantify the risk for CK elevation with statins.
Methods:
This case-control study was conducted at Kaiser Permanente Colorado. Patients with prescriptions for lovastatin or simvastatin between 1 January 1999 and 30 June 2006 were identified. Cases (n = 183), i.e. patients with a CK > or =10x the upper limit of normal (ULN) while receiving a statin during this time period, were each matched on the date of statin purchase to ten control patients (n = 1830) without CK > or =10x ULN while receiving a statin. Multivariate, conditional logistic regression was used to assess the associations between the statin, statin dose, demographic, co-morbidity, laboratory, and medication factors potentially associated with CK >or =10x ULN.
Results:
he mean (SD) age of patients was 64.9 (11.5) years and 56.9% were male. Overall, simvastatin use was associated with a higher likelihood for CK > or =10x ULN than lovastatin (adjusted odds ratio [OR] 4.6; 95% CI 1.1, 12.4). Using simvastatin 40 mg daily as the referent, and in the absence of interacting medications, only simvastatin 80 mg was associated with a higher likelihood for CK > or =10x ULN (OR 2.7; 95% CI 1.1, 6.9). In the presence of interacting medications, all doses of simvastatin and only lovastatin 80 mg were associated with a higher likelihood for CK > or =10x ULN.
Conclusion:
In this study, simvastatin was associated with a higher likelihood for CK > or =10x ULN than lovastatin. High-dose simvastatin, in particular, appears to confer a greater risk than lower doses of either simvastatin or lovastatin.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
01:25Pharmacokinetics: Drug–Drug Interactions
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment